ID | 1203 |
Name of the vaccine | InvaplexAR |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | 18 to 45 years |
Description of the vaccine | Artificial Invaplex vaccine consists of recombinant IpaB, IpaC and wild-type LPS using molar ratios. |
Name of the manufacturer | U.S. Army Medical Research and Development Command |
Name of the manufacturing country | United States |
Year of manufacture | 2016 |
Clinical Phase status | Clinical - Phase 1 |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | Three doses. |
Mechanism of action | Systemic and mucosal vaccine antigen-specific immune response. |
Route of administration | Intranasal |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT02445963 |
Reference | https://www.who.int/immunization/research/meetings_workshops/7.Shigella.Richard_Walker.pdf |
Other name | NA |
Additional Links | NA
|